Biotech and pharmaceutical company stocks got no traction this week from the proposed $2 billion takeover of Alder Biopharmaceuticals or a "largely symbolic" House plan to slash drug prices.
Biotech and pharmaceutical company stocks got no traction this week from the proposed $2 billion takeover of Alder Biopharmaceuticals or a "largely symbolic" House plan to slash drug prices.